These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 17625972)
21. Current status and challenges of antiretroviral research and therapy. Esté JA; Cihlar T Antiviral Res; 2010 Jan; 85(1):25-33. PubMed ID: 20018390 [TBL] [Abstract][Full Text] [Related]
22. [Molecular mehanisms of drug resistance acquisition in HIV]. Sugiura W Nihon Rinsho; 2009 Jan; 67(1):43-51. PubMed ID: 19177751 [TBL] [Abstract][Full Text] [Related]
23. Cenicriviroc, an orally active CCR5 antagonist for the potential treatment of HIV infection. Klibanov OM; Williams SH; Iler CA Curr Opin Investig Drugs; 2010 Aug; 11(8):940-50. PubMed ID: 20721836 [TBL] [Abstract][Full Text] [Related]
24. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro. Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762 [TBL] [Abstract][Full Text] [Related]
25. Tribulations and trials in HIV disease, Part 2. Boyle BA AIDS Read; 2006 Jun; 16(6):291-4. PubMed ID: 16795918 [No Abstract] [Full Text] [Related]
26. Phase 2 study of the safety and efficacy of vicriviroc, a CCR5 inhibitor, in HIV-1-Infected, treatment-experienced patients: AIDS clinical trials group 5211. Gulick RM; Su Z; Flexner C; Hughes MD; Skolnik PR; Wilkin TJ; Gross R; Krambrink A; Coakley E; Greaves WL; Zolopa A; Reichman R; Godfrey C; Hirsch M; Kuritzkes DR; J Infect Dis; 2007 Jul; 196(2):304-12. PubMed ID: 17570119 [TBL] [Abstract][Full Text] [Related]
31. Advances in antiretroviral therapy. Taylor B; Olender S; Wilkin TJ; Hammer SM Top Antivir Med; 2011; 19(2):69-97. PubMed ID: 21868824 [TBL] [Abstract][Full Text] [Related]
32. [AIDS Study Group/Spanish AIDS Plan consensus document on antiretroviral therapy in adults with human immunodeficiency virus infection (updated January 2010)]. ; Enferm Infecc Microbiol Clin; 2010; 28(6):362.e1-91. PubMed ID: 20554079 [TBL] [Abstract][Full Text] [Related]
33. Clinical outcomes improve with highly active antiretroviral therapy in vertically HIV type-1-infected children. Resino S; Resino R; Maria Bellón J; Micheloud D; Gutiérrez MD; de José MI; Ramos JT; Fontelos PM; Ciria L; Muñoz-Fernández MA; Clin Infect Dis; 2006 Jul; 43(2):243-52. PubMed ID: 16779753 [TBL] [Abstract][Full Text] [Related]
34. The current status of, and challenges in, the development of CCR5 inhibitors as therapeutics for HIV-1 infection. Maeda K; Nakata H; Ogata H; Koh Y; Miyakawa T; Mitsuya H Curr Opin Pharmacol; 2004 Oct; 4(5):447-52. PubMed ID: 15351348 [TBL] [Abstract][Full Text] [Related]
35. Dyslipidaemia and cardiovascular risk in HIV infection. Kulasekaram R; Peters BS; Wierzbicki AS Curr Med Res Opin; 2005 Nov; 21(11):1717-25. PubMed ID: 16307691 [TBL] [Abstract][Full Text] [Related]
37. Recent updates for designing CCR5 antagonists as anti-retroviral agents. Shah HR; Savjani JK Eur J Med Chem; 2018 Mar; 147():115-129. PubMed ID: 29425816 [TBL] [Abstract][Full Text] [Related]
38. HAART in HIV/AIDS Treatments: Future Trends. Lu DY; Wu HY; Yarla NS; Xu B; Ding J; Lu TR Infect Disord Drug Targets; 2018; 18(1):15-22. PubMed ID: 28474549 [TBL] [Abstract][Full Text] [Related]
39. Antiretroviral therapy for initial human immunodeficiency virus/AIDS treatment: critical appraisal of the evidence from over 100 randomized trials and 400 systematic reviews and meta-analyses. Kanters S; Mills EJ; Thorlund K; Bucher HC; Ioannidis JP Clin Microbiol Infect; 2014 Feb; 20(2):114-22. PubMed ID: 24274661 [TBL] [Abstract][Full Text] [Related]
40. Protease Inhibitors for the Treatment of HIV/AIDS: Recent Advances and Future Challenges. Voshavar C Curr Top Med Chem; 2019; 19(18):1571-1598. PubMed ID: 31237209 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]